Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Koji, Kashiwagi, Shinichiro, Goto, Wataru, Asano, Yuka, Takahashi, Katsuyuki, Takashima, Tsutomu, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://www.ncbi.nlm.nih.gov/pubmed/29615076
http://dx.doi.org/10.1186/s12967-018-1460-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://www.ncbi.nlm.nih.gov/pubmed/29615076
http://dx.doi.org/10.1186/s12967-018-1460-4

Ejemplares similares